The appearance and dissemination of MDR among pathogenic bacteria has forced the search for new antimicrobials. Bacteriocins have been proposed as potential alternatives for the treatment of infections due to multiresistant strains.
Introduction
Pseudomonas aeruginosa is a Gram-negative bacterium that is intrinsically resistant to a broad range of natural and anthropogenic inhibitors. Owing to its vast metabolic plasticity and its ability to form biofilms, P. aeruginosa can colonize multiple niches, making it a major public health concern.
1,2 It is usually found in soil and natural water sources, and can be isolated from various living sources. In humans, it behaves as an opportunistic pathogen causing both acute and chronic infections, which are especially serious in individuals with compromised immune function such as patients undergoing chemotherapy and patients with AIDS or cystic fibrosis (CF). 3 In CF, the establishment of chronic infection by this microorganism is generally associated with high levels of antibiotic resistance and worsening of the illness. In this context, P. aeruginosa infections are difficult to eradicate and in most cases contribute to early mortality in affected patients. 3, 4 In recent years, the treatment of infections caused by P. aeruginosa has become a challenging task for clinicians due to the high incidence of infections caused by MDR strains. More than 10% of hospital-acquired infections are caused by this versatile pathogen. 2 The emergence and spread of MDR represents a new threat against which traditional antibiotics offer little protection. Although phage therapy was originally proposed as a potential treatment for bacterial infections decades ago, the recent emergence and dissemination of MDR strains from multiple bacterial species has stimulated increased interest in phages as an alternative to antimicrobial treatment. [5] [6] [7] Most bacteria produce antimicrobial compounds, called bacteriocins, supposedly to kill closely related competitors. 8 The chromosome of P. aeruginosa encodes at least three different types of bacteriocins (R-, F-and S-type), referred to as pyocins, whose production is induced in response to DNA-damaging agents. 9 R-pyocins are genetically and structurally related to the contractile tail of P2 bacteriophages, although they lack a phage head V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. structure. 10 When bound to the cell surface of susceptible bacteria, R-pyocins contract their sheath, insert their core structure through the cell envelope and produce depolarization of the cytoplasmic membrane, leading to cell lysis.
11 R-pyocin-specific receptors are located in the LPS molecule. 9 By studying different LPS mutants in P. aeruginosa (wbpP, wbpM, wbpL, rmlC and algC), Köhler et al. 12 deciphered the R-pyocin binding sites in LPS.
Of all the pyocin types produced by this bacterium, R-pyocins show high killing activity (single-hit mechanism that involves one or two active pyocins killing one bacterium), with activity against a plethora of P. aeruginosa strains, 13, 14 in addition to a number of other species such as Campylobacter spp., 15 Neisseria gonorrhoeae,
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Neisseria meningitidis, 17 Haemophilus ducreyi, 18 Pseudomonas fluorescens and Pseudomonas putida.
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Considering the current necessity of finding new antimicrobials, there has been interest in R-pyocins as specific bactericidal agents in recent years. [20] [21] [22] The antibacterial efficacy of engineered R-pyocins has been demonstrated in a mouse model of P. aeruginosa peritonitis 22 and in food products contaminated by Escherichia coli O157:H7. 23 Five different types of R-pyocins have been described on the basis of their killing activities 24 and of the amino acid sequences of the tail fibre protein Prf15 (PA0621 of PAO1). The sequence of the tail fibre proteins of the R2-, R3-and R4-pyocins are nearly identical. However, the sequence of the C-terminal region of the Prf15 protein from R1-and R5-pyocins differs considerably. 21 Therefore, R-pyocins can be classified into three types: R1, R2 and R5.
In the present study, we analysed the activity of R-pyocins (R1, R2 and R5) against clinical isolates of P. aeruginosa from patients with CF and other sources, to evaluate them as a potential adjuvant or alternative to antibiotic treatment.
Methods

Bacterial strains and media
In total, 254 P. aeruginosa clinical isolates were studied. This collection included well-characterized isolates from the Son Espases University Hospital of Palma de Mallorca: 25, 26 120 isolates from CF patients and 30 isolates from patients with bloodstream infection. Additionally, 104 isolates from varied sources (bronchial aspirates, sputum, skin, abdomen, urine etc.) from the Virgen del Rocío University Hospital (HUVR) were also studied. Patient, source of isolation and PFGE data suggested that all strains were non-replicate isolates. All P. aeruginosa clinical isolates used in this work are listed in Tables S1 and S2 (available as Supplementary data at JAC Online). Pseudomonas laboratory strains and R-pyocin indicator strains are listed in Table 1 (Pseudomonas R-pyocin indicator strains were a kind gift from Dr Köhler).
Bacterial cultures were grown in LB medium at 37 C with agitation (200 rpm).
R-pyocin susceptibility assays
A set of indicator strains was used to perform spot assays. PAK, PA14 and 15108 were used as R1, R2 and R5 pyocin sources, respectively, while WT PAO1 and its derivative mutants wbpM, wbpL, algC, rmd and rmlC were used as controls for testing pyocin susceptibility (Table 1) .
Pyocin extracts were obtained as detailed in Köhler et al. 12 with minor variations. Briefly, R-pyocin producer strains were grown overnight in 5 mL of LB medium at 37 C with agitation (200 rpm) and cultures were centrifuged at 14 000 rpm for 5 min. To kill residual bacterial cells, 250 lL of chloroform was added to each supernatant. The resulting supernatant was used as a source of R-pyocins. Clinical strains were grown overnight in LB medium and diluted to obtain an OD at 600 nm of 0.64. Three microlitres of each suspension was added to 3 mL of top agar and poured onto fresh LB medium plates. For the spot assay, 10 lL of each supernatant was deposited on the top agar and plates were incubated overnight at 37 C. Clear halos (lysis) were considered as a positive result for R-pyocin activity. As negative control for R-pyocin production, susceptibility assays were performed using supernatants from strains carrying essential deletions for R-pyocin synthesis (PAKDR1, PA14DR2 and 15108DR5). When supernatants from non-producer strains produced lysis halos on lawns of tested isolates, lysis activity was not considered a result of R-pyocin activity and was scored as negative.
R-pyocin concentration in each supernatant was estimated with the Bradford protein assay following the instructions of the manufacturer (BioRad Laboratories, Inc.). The results were expressed in lg of total protein/mL.
Antibiotic susceptibility profiles
Antibiotic susceptibilities of clinical isolates were determined by broth microdilution according to EUCAST recommendations. 27 
Synergy studies of pyocins and antipseudomonal agents
Interactions between R-pyocins and antipseudomonal agents (imipenem, ciprofloxacin, levofloxacin, tobramycin, gentamicin, amikacin and colistin) were quantitatively studied by the chequerboard method and analysed according to EUCAST recommendations. The fractional inhibitory concentration (FIC), which is the quotient of the MIC of a drug in combination and the MIC of the drug acting alone, was calculated. The FIC index (FICI) represents the sum of the FICs of each drug tested. Synergy was considered when FICI 0.5, no interaction when FICI .0.5 but 4, and antagonism when FICI .4.
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Serotyping O-antigen serotypes (O1-O16) of P. aeruginosa isolates were determined by agglutination using serotype-specific antisera (Bio-Rad, codes: 58901-58916) in accordance with the instructions of the manufacturer. R-pyocin susceptibility of P. aeruginosa strains
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Statistical analysis
All statistical analyses were performed using R-commander (Rcmdr, version 2.1-7). Pearson's v 2 test was used with significance level 0.05 unless the expected frequency was lower than 5, in which case Fisher's exact test was applied.
Results
Cystic fibrosis isolates show higher susceptibility to R-pyocins
Two different groups of clinical isolates were studied. The first group included a subset of 34 isolates from CF patients, corresponding to different clones (CF group, chronic infection), and the second group included 30 isolates from the bloodstream (non-CF group, acute infection) (see the Methods section). The R-pyocin susceptibility pattern was analysed by spot assays in both groups. Similar susceptibility profiles for each R-pyocin type were found among CF and non-CF isolates, with no significant differences between R1, R2 and R5 (61.76%, 64.7% and 64.7% of CF isolates and 26.7%, 40% and 40% of non-CF isolates were lysed by R1, R2 and R5, respectively) ( Figure 1 and Table S1 ). However, comparing R1-, R2-and R5-pyocin susceptibility patterns between groups (CF and non-CF) demonstrated a statistically significant difference: 61.76% versus 26.7% for R1-pyocin (v 2 " 7.9228, df " 1, P value " 0.005); 64.7% versus 40% for R2-pyocin (v 2 " 3.906, df " 1, P value " 0.048); and 64.7% versus 40% for R5-pyocin (v 2 " 3.906, df " 1, P value " 0.048). This is even more dramatic when we consider isolates susceptible to at least one out of the three R-pyocins, where we find that 79.41% of CF strains were susceptible to R-pyocins versus 50% in non-CF strains (v 2 " 6.111, df " 1, P value " 0.013). Therefore, CF isolates showed higher susceptibility to R1, R2 and R5 compared with isolates from other sources.
We wanted to determine if this behaviour occurred in other isolates, therefore we analysed the pyocin susceptibility patterns of 104 isolates of P. aeruginosa from HUVR (Table S2) . Although these isolates came from different anatomical sites, they all caused acute infections in patients. The susceptibility pattern to R-pyocins was similar to that of isolates from bacteraemia (39.42% of isolates showed susceptibility to R1, 44.2% to R2, 40.4% to R5 and 55.76% to at least one out of the three R-pyocins; see the statistical analysis available as Supplementary data at JAC Online).
Correlation between serotype and R-pyocin susceptibility
Since sugar residues of the LPS O-specific antigen (OSA) are part of the receptor sites for R1-, R2-and R5-pyocins, 12 we determined the O-antigen serotypes of all clinical isolates included in Figure 1 ( Table S1 ).
Serotyping reveals that 15 out of 34 CF isolates did not agglutinate with specific O-antiserum (non-typeable) suggesting the loss of the variable fraction O-antigen. Among non-CF isolates, only 4 out of 30 were non-typeable. The most frequently encountered serotypes were O1-type (7) within CF isolates and O6-type (9), O7-type (4) and O12-type (4) within non-CF isolates. Our results agree with previous observations for chronic strains. 28, 29 We found an increased percentage of non-typeable isolates among CF isolates (44.12% of CF isolates versus 13.33% of non-CF isolates, v 2 " 7.235, P value " 0.007). Among non-typeable strains, 86.7% of CF isolates were susceptible to R-pyocins (R1, R2 or R5) compared with 25% of non-CF isolates (P value " 0.03). In contrast, no significant differences were found for typeable strains (73.7% of CF isolates versus 53.8% of non-CF isolates, P value " 0.17; see the statistical analysis available as Supplementary data at JAC Online).
Noticeably, 9 out of 10 O1-type isolates were susceptible to Rpyocins and all 10 O6-type isolates showed susceptibility to R2-or R5-pyocin.
R-pyocin susceptibility evolution in CF patients
A total of 100 typed isolates (10 longitudinal isolates taken over an 8 year period from 10 CF patients), previously described by López-Causapé et al., 26 were used to study the evolution of susceptibility to R-pyocins over time. Spot assays revealed a few changes in susceptibility to R1-, R2-and R5-pyocins of clinical strains from 10 CF patients throughout the course of their illness ( Figure 2 and Table S3 ). The ST clones isolated from patients 2, 3, 4, 6, 7, 9 and 10 were the same during the entire study period (ST274, ST274, ST701, ST274, ST1073, ST1089 and ST1071, respectively), except a single isolate in patient 4 (ST254) and in patient 6 (ST1089). Susceptibility to R-pyocins remained stable over 8 years among the patients infected with one ST clone, with the exception of some isolates from patients 3, 6 and 7. The occurrence of R-pyocin resistance seems to be an event not associated with the mutator phenotype, pigmentation or morphology (Table S3 ). Despite the fact that an increased mutation rate was observed for clones ST1073, ST1089 and ST299, no association was found between mutation rate and R-pyocin resistance, suggesting that hypermutation does not impact R-pyocin resistance, as is the case for antibiotic resistance. 26, 30 We also characterized R-pyocin production in 34 different clones (unique STs) using the indicator strains listed in Table 1 (PAO1 mutants algC, rmlC, wbpL, wbpM and rmd). Most of them Redero et al.
did not produce R-pyocins, except two invading clones from patient 8 that produced pyocin R1 (Table S4 ). Some of them produced a diffuse halo over indicator strain lawns suggesting the production of another inhibitor.
Correlation between antibiotic and R-pyocin susceptibility profiles
Antibiotic and R-pyocin susceptibility patterns to six conventional antibiotics used in clinical practice against P. aeruginosa (ceftazidime, imipenem, meropenem, ciprofloxacin, tobramycin and colistin) were studied for 34 P. aeruginosa strains with unique STs from CF patients and 30 isolates from patients with bloodstream infection (non-CF). The v 2 test showed no relationship between R-pyocin and antibiotic resistance for either CF isolates or non-CF isolates (MIC values are shown in Table S5 ).
Aminoglycoside resistance has been associated with changes in LPS (from smooth to rough). 31 Among non-typeable isolates in our set, 3 out of 19 were resistant to tobramycin (of those, only one was resistant to R-pyocins). A reduction in the number of LPS molecules has also been associated with colistin resistance. 32 Only one colistin-resistant isolate was identified among 19 nontypeable strains.
Interactions between R-pyocins and antipseudomonal agents
To assess the therapeutic use of R-pyocins in combination with standard treatments for P. aeruginosa infections, interactions between R-pyocins and antipseudomonal antibiotics were quantitatively evaluated by the use of the chequerboard method according to EUCAST recommendations. 27 Isolates from different groups were chosen: three CF isolates (FQSE36-1111, FQSE02-1102-3 and FQSE12-1007), one laboratory strain (PAK wbpP) and two XDR/MDR nosocomial isolates (PA1016 and PA116, both belonging to the ST175 clone, which is considered a high-risk clone). 33 No interaction was found between R-pyocins and standard antipseudomonal antibiotics for the strains PA116, PAK wbpP, FQSE36- Figure 2 . Evolution of R-pyocin susceptibility of P. aeruginosa isolates from CF patients. Susceptibility to R-pyocins of sequential isolates from CF patients over 8 years. White rectangles show R-pyocin-susceptible isolates and striped rectangles correspond to resistant isolates. An asterisk indicates a mutator isolate. ST clones are indicated; ST274 and ST1089 belong to the same PFGE clonal type.
R-pyocin susceptibility of P. aeruginosa strains JAC 1111, FQSE02-1102-3 and FQSE12-1007 ( Table 2 ). The FICI was between 0.62 and 1. Interestingly, a synergic effect between R2-pyocin and tobramycin and between R2-pyocin and gentamicin was observed for strain PA1016 (ST175) (FICI 0.28 and 0.08 respectively).
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Discussion
The search for new effective antimicrobials to fight P. aeruginosa infections is a priority, especially in the context of CF, where the isolation of this bacterium is associated with a poorer disease progression. 34 Research in phage therapy is slowly resurging, 7 mainly due to the lack of development of new antibiotics. Pyocins are bacteriocins of phage origin produced by P. aeruginosa strains, supposedly for intra-species competition purposes, 8 although they are also active against non-related species. Notably, R-pyocins exhibit narrow bactericidal spectra and thus can be expected to have little effect on healthy microbiota. Also, they are not replicative structures (they do not contain DNA) and therefore they cannot promote the horizontal spread of MDR among other bacteria, which is a desirable characteristic for a therapeutic agent.
In the present study we compared isolates from CF patients, where the infection caused by this pathogen becomes chronic in later stages and a plethora of regulatory networks play a role in adaptation, 35, 36 with isolates from patients with bloodstream infection, where infections are usually acute. 37 Our results show that P. aeruginosa isolates from cystic fibrosis patients are more susceptible to R-pyocins. Almost 80% of the CF isolates were susceptible to at least one out of the three R-pyocins, while only 50% of isolates from bloodstream infections showed susceptibility. This pattern was also demonstrated in isolates that caused acute infection from a different hospital (HUVR).
Little is known about the R-pyocin susceptibility pattern of P. aeruginosa clinical isolates. Köhler et al. 12 described the R-pyocin susceptibility profile of 47 isolates from tracheal aspirates. They found a similar proportion of isolates susceptible to R-pyocins (59% versus 50% in our study). They also analysed the R-pyocinproduction profile and demonstrated a similar percentage of nonproducers and R1, R2 and R5 producers (17%-29%). The R-pyocin deficient isolates were susceptible to R1-, R2-and R5-pyocins, while most R2-and R5-pyocin producers were resistant. 12 Ghoul et al. 38 also used clinical isolates from CF patients and non-lung sources to study the role of pyocins in the dynamism of lung colonization. They concluded that isolates taken from strains causing chronic infections produce fewer types of pyocins and, at the same time, are more susceptible to pyocins produced by other strains than the strains causing acute infections. These findings are in agreement with the high susceptibility to R-pyocins of CF isolates in our collection.
The majority of strains of P. aeruginosa isolated from CF patients display the loss of O-serotype reaction (non-typeable) and susceptibility to normal human serum 28, 29 suggesting defects in LPS (e.g. loss of OSA). Our results are in agreement with previous publications as some CF isolates were also non-typeable. Interestingly, O1-and O6-type isolates showed increased susceptibility to R-pyocins suggesting that some LPS conformations may enable R-pyocins to find their targets. A previous study has also identified O1-and O6-types as highly susceptible serotypes. 12 Our results point to LPS architecture as the ultimate cause of R-pyocin susceptibility in CF isolates. The loss of O-antigen or evolution towards more accessible O- Redero et al.
types in chronic isolates may render these strains more susceptible to R-pyocins. R-pyocin resistance is caused by modifications in the LPS molecule. 19 Our evolutionary study carried out with 10 CF patients for 8 years revealed a few changes in the R-pyocin susceptibility profile over time (among the patients infected with one ST clone), suggesting that these modifications are not very frequent in the lung environment. In addition, most of the patients were colonized by one or two clones. Almost no changes in R-pyocin susceptibility were observed in clones that remain for years, some of them mutators (patients 2, 3, 9 and 10), in contrast to antibiotic resistance, which is developed throughout the illness. 17 Our results are in contrast to those obtained by Köhler et al. 12 where a short evolution of 20 days in a patient's lung was monitored. They showed that a pyocin-producer clone, which was resistant to its own and the other colonizing clone pyocin, replaced the susceptible one. However, 20 days of colonization represent a very different scenario for a CF patient compared with the years of evolution considered in our study and others. For instance, Ghoul et al. 38 carried out a long-term study of infection within patients (6-10 years). Overall, the pyocin susceptibility profile did not change over time, in agreement with our results from patients 2, 4, 9 and 10. They found no support for the hypothesis that certain strains are dominant in the CF lung through pyocins. Along those lines, our results suggest that isolates able to reach the latest stages of infection are more susceptible to R-pyocins and produce fewer R-pyocins. The biological cost of pyocin production, together with the envelope peculiarities selected within the host, likely constitute a handicap in the context of infection.
We did not find a correlation between the susceptibility profile to R-pyocins and common antibiotics currently used in clinical practice for Pseudomonas infections. In the late 1980s, a study including 116 P. aeruginosa isolates from diverse clinical sources (which were not mentioned), 39 suggested a potential relationship between multiple antibiotic resistance (carbenicillin and gentamicin) and susceptibility to R2-pyocins. These authors suggested the impairment of the outer membrane permeability caused by LPS modifications as the likely cause. Carbenicillin and gentamicin have not been studied in this work. However, we studied tobramycin and colistin, which cause alterations in membrane permeability, 40, 41 and our results show that isolates susceptible to Rpyocins were not more susceptible to colistin or aminoglycosides.
Moreover, no interaction was found between antipseudomonal antibiotics and R-pyocins, i.e. the activity of both agents was not affected. The lack of interaction between aminoglycosides or colistin and R-pyocins indicate that they must be targeting different LPS components.
Surprisingly, we did find interaction between R2-pyocin and aminoglycosides (tobramycin and gentamicin) for strain PA1016 (resistant to gentamicin and tobramycin). In contrast, no synergy was observed for the PA116 strain (also resistant to gentamicin and tobramycin). PA1016 and PA116 are both susceptible to R2-pyocin. Therefore, this interesting interaction seems to be specific to the PA1016 strain and requires further investigation.
In summary, here we provide evidence that R-pyocins could be a valuable therapeutic alternative, alone or as adjuvants, in the treatment of P. aeruginosa infections, particularly in CF patients, where their isolates show a high susceptibility to these agents. Future studies addressing issues such as stability, effect on pulmonary epithelial cells and routes of administration are necessary before the possible clinical application of pyocins for lung infection.
